enGene Therapeutics Inc.
Organization details
- Legal name
- enGene Therapeutics Inc.
- Former names
- enGene Holdings Inc.
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2836 — Biological Products, (No Diagnostic Substances)
- Jurisdiction of incorporation
- Canada (Federal Level)
- Headquarters city
- Saint-Laurent
- Headquarters country
- Canada
- Fiscal year end
- October
- Ticker symbol
- ENGN
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001980845
Board of directors
-
Gerald A. Brunk · DirectorSince 2023
-
Jason David Hanson · Director · Chief Executive OfficerSince 2023
-
Jasper Bos · DirectorSince 2023
-
Lota S. Zoth · DirectorSince 2023
- Since 2025
-
Paul J. Hastings · DirectorSince 2024
-
Philip Astley-Sparke · DirectorSince 2025
-
Richard M. Glickman · DirectorSince 2023
-
Ronald Harold Wilfred Cooper · Director · CEO & PresidentSince 2024
-
William Grossman · Director · Interim Chief Medical OfficerSince 2025
-
Wouter Joustra · DirectorSince 2024
Chief executives
Weak · grade F
Out of 100, from shareholder return, dividends, growth and acquisitions.
Partial: only 15% of the scoring weight is on file.
- Earnings growth 15%
- 0
-87.7% a year in earnings per share
15% of the scoring weight is on file. Figures cover October 2023 – October 2025.
Director election results
Annual meeting of June 9, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
99.4%
-
99.8%
-
100.0%
-
100.0%
Board connections
8 of this board's directors also sit on 15 other boards. 14 are in the same sector.
-
Adial Pharmaceuticals Inc Same sectorvia Paul J. Hastings
-
Avalo Therapeutics Inc. Same sectorvia Michael Thomas Heffernan
-
Biohaven Ltd. Same sectorvia Michael Thomas Heffernan
-
Braveheart Bio Inc. Same sectorvia Jasper Bos
-
Bullfrog AI Holdings Inc. Same sectorvia Jason David Hanson
-
C4 Therapeutics Inc. Same sectorvia Ronald Harold Wilfred Cooper
-
Collegium Pharmaceutical Inc. Same sectorvia Michael Thomas Heffernan
- via Lota S. Zoth
-
Inovio Pharmaceuticals Inc. Same sectorvia Lota S. Zoth
-
NewAmsterdam Pharma Company N.V. Same sectorvia Wouter Joustra
-
Nkarta Inc. Same sectorvia Paul J. Hastings
-
Pacira BioSciences Inc. Same sectorvia Paul J. Hastings
-
Replimune Group Inc. Same sectorvia Philip Astley-Sparke
-
Trevi Therapeutics Inc. Same sectorvia Michael Thomas Heffernan
-
Vor Biopharma Inc. Same sectorvia Wouter Joustra
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $10,051
- 1 purchase by 1 insider
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 22, 2026 | William Grossman Director, Officer (Interim Chief Medical Officer) | Open-market purchase | +5,102 | $1.97 | $10,051 |
| Oct 30, 2024 | Forbion Growth Management B.V. 10% owner | Open-market purchase | +561,797 | $8.90 | $4,999,993 |
| Oct 8, 2024 | Forbion Growth Opportunities Fund I Cooperatief U.A. 10% owner | Open-market purchase | +800 | $6.60 | $5,280 |
| Oct 7, 2024 | Forbion Growth Opportunities Fund I Cooperatief U.A. 10% owner | Open-market purchase | +11,844 | $6.55 | $77,578 |
| Oct 4, 2024 | Forbion Growth Opportunities Fund I Cooperatief U.A. 10% owner | Open-market purchase | +5,997 | $6.54 | $39,220 |
| Oct 3, 2024 | Forbion Growth Opportunities Fund I Cooperatief U.A. 10% owner | Open-market purchase | +5,769 | $6.48 | $37,383 |
| Oct 2, 2024 | Forbion Growth Opportunities Fund I Cooperatief U.A. 10% owner | Open-market purchase | +10,153 | $6.37 | $64,675 |
| Oct 1, 2024 | Forbion Growth Opportunities Fund I Cooperatief U.A. 10% owner | Open-market purchase | +35,279 | $6.44 | $227,197 |
| Sep 30, 2024 | Forbion Growth Opportunities Fund I Cooperatief U.A. 10% owner | Open-market purchase | +341,332 | $6.34 | $2,164,045 |
| Sep 27, 2024 | Ronald Harold Wilfred Cooper Director, Officer (Chief Executive Officer) | Open-market purchase | +10,000 | $5.70 | $57,000 |
| Sep 27, 2024 | Forbion Growth Opportunities Fund I Cooperatief U.A. 10% owner | Open-market purchase | +38,396 | $5.94 | $228,072 |
| Sep 27, 2024 | Forbion Growth Opportunities Fund I Cooperatief U.A. 10% owner | Open-market purchase | +3,243 | $6.38 | $20,690 |
| May 28, 2024 | Richard M. Glickman Director | Option exercise | +120 | $0.89 | $107 |
| Apr 22, 2024 | FONDS DE SOLIDARITE DES TRAVAILLEURS DU QUEBEC 10% owner | Open-market sale | −47,854 | $15.00 | $717,810 |
| Apr 19, 2024 | FONDS DE SOLIDARITE DES TRAVAILLEURS DU QUEBEC 10% owner | Open-market sale | −100 | $15.00 | $1,500 |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about enGene Therapeutics Inc.
Who is the CEO of enGene Therapeutics Inc.?
Ronald Harold Wilfred Cooper has been enGene Therapeutics Inc.'s Chief Executive Officer since July 2024.
How many directors are on enGene Therapeutics Inc.'s board?
enGene Therapeutics Inc.'s board has 11 directors: Gerald A. Brunk, Jason David Hanson, Jasper Bos, Lota S. Zoth, Michael Thomas Heffernan, Paul J. Hastings, Philip Astley-Sparke, Richard M. Glickman, Ronald Harold Wilfred Cooper, William Grossman and 1 other.
Are enGene Therapeutics Inc. insiders buying or selling shares?
Over the last 12 months, enGene Therapeutics Inc. insiders bought $10,051 of shares in 1 purchase and made no open-market sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="engene-therapeutics-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.